Interleukin-2 muteins for the expansion of T-regulatory cells

US9932380B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Marc A. Gavin · Vashon, US
• Gunasekaran Kannan · Daly City, US
• Li Li · Stanford, US
• Joshua T. Pearson · San Francisco, US
• Margaret Karow · Newbury Park, US

Key dates

• Filing date: Jan 17, 2017
• Grant date: Apr 3, 2018
• Expiry date: Jan 17, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/43
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.